BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

It was a busy week for the biotech sector as usual, with lots of regulatory and pipeline updates, before the first-quarter ...

The lack of effect on QoL and oxygen consumption help cement the idea that the disease isn’t the same as obstructive HCM.

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos ...

In the Phase III ODYSSEY-HCM trial, patients treated with Camzyos for symptomatic non-obstructive hypertrophic cardiomyopathy did not show significant improvements based on Kansas City Cardiomyopathy ...

Princeton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment ...

The dual-primary endpoints for the trial were to examine changes from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2 ...

In the ODYSSEY-HCM (NCT05582395) trial, the cardiac myosin inhibitor did not show a benefit compared to placebo in either the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) ...